The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...

While Verzenio, a drug in the same class, has been approved to lower the risk of early breast cancer returning, it's only for ...

A recent survey from AARP found that roughly 40 percent of adults age 65-plus who are eligible for Medicare have either ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Last year, the Community Oncology Alliance sued to reverse a policy that prohibits oncology practices from mailing cancer ...

In today’s “AARP Minute,” how some people taking chemotherapy drugs are saving thousands of dollars, plus a new poll shows a ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Research undertaken at the Harry Perkins Institute of Medical Research in Perth has shown that administering anti-cancer ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...